182 related articles for article (PubMed ID: 34990854)
1. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
Perez-Correa A; Abbas B; Riback L; Ghiroli M; Norton B; Murphy S; Jakubowski A; Hayes BT; Cunningham CO; Fox AD
Contemp Clin Trials; 2022 Mar; 114():106674. PubMed ID: 34990854
[TBL] [Abstract][Full Text] [Related]
2. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
[TBL] [Abstract][Full Text] [Related]
3. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Jakubowski A; Fowler S; Fox AD
Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
[TBL] [Abstract][Full Text] [Related]
4. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
5. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
[No Abstract] [Full Text] [Related]
6. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
8. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
[TBL] [Abstract][Full Text] [Related]
9. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
[TBL] [Abstract][Full Text] [Related]
11. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
[TBL] [Abstract][Full Text] [Related]
12. Treatment access for opioid use disorder in pregnancy among rural and American Indian communities.
Kelley AT; Smid MC; Baylis JD; Charron E; Begaye LJ; Binns-Calvey A; Archer S; Weiner S; Pettey W; Cochran G
J Subst Abuse Treat; 2022 May; 136():108685. PubMed ID: 34953636
[TBL] [Abstract][Full Text] [Related]
13. Descriptive study: the novel "full spectrum people-with-opioid-use-disorder care model".
Gadomski R; Bhatt S; Gross J; Dixon JA; Fiuty P; Shapiro M; Fernandez-Mancha R; Salvador J
Harm Reduct J; 2023 Apr; 20(1):47. PubMed ID: 37046265
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
15. A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD).
Khatri UG; Lee K; Lin T; D'Orazio JL; Patel MS; Shofer FS; Perrone J
J Med Toxicol; 2022 Jul; 18(3):205-213. PubMed ID: 35415804
[TBL] [Abstract][Full Text] [Related]
16. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
Huo S; Heil J; Salzman MS; Carroll G; Haroz R
J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
[TBL] [Abstract][Full Text] [Related]
17. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
19. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
Parlier-Ahmad AB; Pugh M; Martin CE
J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
[TBL] [Abstract][Full Text] [Related]
20. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
